Trial of Aripiprazole in the Treatment of CD in Adolescents
Status:
Completed
Trial end date:
2009-03-23
Target enrollment:
Participant gender:
Summary
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment
of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct
disorder. The initial dose depending on the weight of the patient will be as follows: < 25 kg
= 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003,
Bristol-Myers Squibb). For the first two weeks of the study, the dose will be flexible based
on response and tolerance and thereafter will remain fixed.